Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine
Pain Medicine · 01.01.2026 · 27 (1) · 86-94
DOI: 10.1093/pm/pnaf089 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Pain Medicine, online erschienen am 08.07.2025. Verfasst von Seth Lederman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Tonix Pharmaceuticals, Inc., Chatham, NJ 07928, United States. Hauptthemen laut MEDLINE: Fibromyalgia, Amitriptyline, Pain Management, Sleep Wake Disorders. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tonix Pharmaceuticals.
Abstract (Originalsprache)
Objective
Fibromyalgia is the prototypic nociplastic chronic pain syndrome, characterized by widespread pain, nonrestorative sleep, and fatigue. We evaluated efficacy and safety of bedtime TNX-102 SL (sublingual cyclobenzaprine) 5.6 mg for treatment of fibromyalgia.
Methods
This phase 3, double-blind, multicenter, placebo-controlled trial randomized patients 1:1 to once-nightly TNX-102 SL 2.8 mg for 2 weeks, followed by 5.6 mg for 12 weeks, or to matching placebo (NCT05273749). The primary endpoint was change from baseline at week 14 in weekly average of daily diary pain intensity scores. Secondary endpoints included Patient Global Impression of Change, Fibromyalgia Impact Questionnaire (Revised) Symptoms and Function domains, Patient-Reported Outcomes Measurement Information System instruments for Sleep Disturbance and Fatigue, and daily diary sleep quality scores.
Results
Overall, 81.0% (n = 187/231) and 79.6% (n = 179/225) of patients receiving TNX-102 SL and placebo completed the trial, respectively. Treatment with TNX-102 SL vs placebo was associated with significantly greater reductions in the primary pain endpoint (P < .001; mean [SE], −1.8 [0.12] vs −1.2 [0.12]) and in each of the 6 secondary endpoints (P ≤ .001; all). The most common systemic treatment-emergent adverse events (TEAEs) with TNX-102 SL and placebo were COVID-19 (4.3% vs 3.1%, respectively), headache (3.0% vs 1.8%), and somnolence (3.0% vs 1.3%); the most common TEAEs overall were local administration-site reactions including oral hypoesthesia (23.4% vs 0.4%), product taste abnormal (11.3% vs 0.9%), and oral paresthesia (6.9% vs 0.9%), which were transient and self-limited.
Conclusion
Bedtime TNX-102 SL treatment was associated with significant improvements in fibromyalgia symptoms and function and was well tolerated. Clinical trial registration ClinicalTrials.gov/study/NCT05273749, first patient screened March 21, 2022.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tonix Pharmaceuticals, Inc., Chatham, NJ 07928, United States.
- University of Cincinnati College of Medicine, Cincinnati, OH 45267, United States.
- Rho Inc., Chapel Hill, NC 27713, United States.
ORCID-Profile: Seth Lederman, Lesley M Arnold, Ben Vaughn, Jean M Engels, Mary Kelley, Gregory M Sullivan
Förderung
- Tonix Pharmaceuticals
Zitieren
APA
Lederman, S., Arnold, L. M., Vaughn, B., Engels, J. M., Kelley, M., & Sullivan, G. M. (2026). Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine. Pain Medicine, 27(1), 86-94. https://doi.org/10.1093/pm/pnaf089
Vancouver
Lederman S, Arnold LM, Vaughn B, Engels JM, Kelley M, Sullivan GM. Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine. Pain Medicine. 2026;27(1):86-94. doi:10.1093/pm/pnaf089
BibTeX
@article{Lederman2026,
author = {Lederman, Seth and Arnold, Lesley M and Vaughn, Ben and Engels, Jean M and Kelley, Mary and Sullivan, Gregory M},
title = {Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine},
journal = {Pain Medicine},
year = {2026},
volume = {27},
number = {1},
pages = {86--94},
doi = {10.1093/pm/pnaf089}
}
EUVIMED